

SHORT COMMUNICATION

Association of mortality and phase angle measured by different bioelectrical impedance analysis (BIA) devices

Laurence Genton¹, François. R. Herrmann², Adrian Spörri³, Christophe E. Graf⁴

¹ Clinical Nutrition, University Hospitals of Geneva, Switzerland

² Geriatrics, Dept. Internal Medicine, Rehabilitation and Geriatrics, University Hospitals of Geneva, Switzerland

³ Social and Preventive Medicine, University of Bern, Switzerland

⁴ Rehabilitation and palliative Care, University Hospitals of Geneva, Switzerland

Date: 11 July 2017

Article content: 1578 words, 3 tables

Short title: Phase angle and mortality in older people

Keywords: phase angle, mortality, bioelectrical impedance analysis

Abbreviations: BIA: bioelectrical impedance analysis. BMI: body mass index. CIRS: Cumulative Illness Rating Scale.

Correspondence:

Laurence Genton, Clinical Nutrition

Rue Gabrielle Perret-Gentil 4, Geneva University Hospitals, 1205 Geneva, Switzerland

Phone: +41 22 3729344 Fax: +41 22 3729363

E-mail: laurence.genton@hcuge.ch

1 **Abstract**

2 **Purpose:** A high phase angle measured by the Nutriguard[®] bioelectrical impedance analysis
3 device is associated with a reduced mortality risk in older people. This retrospective study
4 aims to analyze whether this association persists with the other devices that have been used in
5 our hospital.

6 **Methods:** This study encompasses all people 65 yrs and older who underwent a phase angle
7 measurement between 1990 and 2011 at the Geneva University Hospitals, with the RJL-101[®]
8 (RJL Systems), Xitron 4000B[®] (Xitron Technologies), Eugedia[®] (Eugédia-Spengler) and Bio-
9 Z[®] (Spengler). Diseases at the time of phase angle measurement were reported in the form of
10 the Cumulative Illness Rating Scale. Date of death was retrieved until December 2012. Phase
11 angle values were categorized into sex- and device-specific quartiles, where quartile 1
12 represents the lowest quartile and reference value. Cox regressions were performed to
13 evaluate the association between phase angle quartiles and mortality.

14 **Results:** We considered 1878 people (969 women), of whom 1151 had died. In univariate
15 sex-specific Cox regressions, the death risk decreased progressively as the phase angle
16 quartile measured by the Bio-Z[®] or RJL-101[®] increased. The HR (95% CI) in quartile 4 was
17 0.36 (0.26, 0.50) and 0.38 (0.29, 0.52) in women and men measured with the Bio-Z[®] (both
18 $p < 0.001$), and 0.23 (0.14, 0.39) and 0.19 (0.10, 0.36) in women and men measured with the
19 RJL-101[®] (both $p < 0.001$). The association between phase angle and mortality persisted when
20 adjusted for age, body mass index or co-morbidities. The small number of deaths in people
21 who underwent a measurement by Eugedia[®] (n=93) or Xitron4000B[®] (n=56) did not allow
22 performing multivariate Cox regressions.

23 **Conclusions:** Phase angle quartiles are associated with mortality in people aged >65 years
24 when using the RJL-101[®] or Bio-Z device[®].

25

26 **Keywords:** bioimpedance, older people, death

27 **Introduction**

28 An increasing interest arises in the potential of phase angle to predict adverse outcomes
29 like mortality (1-3). Phase angle is a raw bioelectrical impedance analysis (BIA)-derived
30 parameter which may reflect cell size, cell membrane integrity and/or the distribution of water
31 in the extra- and intracellular compartments (4) (5). Mathematically, it can be obtained from
32 the arctangent of the reactance to resistance ratio measured by BIA. Thus, phase angle values
33 do not depend on equations and their inherent assumptions, in contrast to BIA-derived body
34 composition, i.e. fat mass and fat-free mass.

35 In a recently published cohort study, we have included all people ≥ 65 yrs who had
36 undergone a BIA measurement at the Geneva University Hospitals between 1990 and 2011
37 (n=3181) (6). Mortality was reported until December 2012. We have shown that the lower the
38 phase angle quartile at the last BIA measurement performed with the Nutriguard[®] device
39 (n=1307) (Data Input GmbH, Darmstadt, Germany), the higher was the death risk,
40 independently of the co-morbidities (7). We had focused on the measurements performed
41 with the Nutriguard[®] device because 1) this device is still used in our hospital, and 2) phase
42 angle reference values using the same brand of BIA device have been published (8) and
43 allowed us to standardize the values for age and body mass index (BMI).

44 However, we have not reported the association of mortality and the phase angle measured
45 by the other BIA devices that we have used over the time span of 21 years. The rationale of
46 performing additionally these analyses is that, in the absence of a gold standard, phase angle
47 values likely differ between devices. This retrospective study aims to analyze whether phase
48 angle values measured by the other BIA devices than the Nutriguard[®] are also associated with
49 mortality.

50

51 **Material and methods**

52 We included the remaining 1878 people of our previously described cohort study (6),
53 which encompassed all people ≥ 65 yrs who underwent a BIA measurement at the Geneva
54 University Hospitals between 1990 and 2011. This study population included hospitalized
55 and ambulatory patients followed in clinical routine by the nutrition unit, and healthy people
56 recruited for research purpose in leisure clubs, the hospital staff, at fun runs and through
57 advertisement in local newspapers. The proportion of hospitalized patients was about 50%
58 (n=967). BIA measurements were performed at 50kHz and 0.8 mA, while the subject was
59 lying in the supine position with electrodes placed on the right hand, wrist, ankle and foot.
60 The following devices were used: RJL-101[®] (1990 to 1995) (RJL Systems, Inc., Clinton
61 Township MI, USA), Xitron 4000B[®] (1990 to 2011) (Xitron Technologies, San Diego, CA,
62 USA), Eugedia[®] (1994 to 2000) (Eugédia-Spengler, Cachan, France) and Bio-Z[®] (1996 to
63 2002) (Spengler, Paris, France). All devices were calibrated for phase angle with a
64 calibration jig (CJ 4000, Xitron Technologies, San Diego, CA, USA), before their use in our
65 institution. A limit of $\pm 2^\circ$ for phase angle and $\pm 5\Omega$ for impedance was tolerated at 50 kHz. To
66 test method agreement, we had measured the phase angle values of 8 healthy people with the
67 RJL-101[®], the Xitron[®], and the Bio-Z[®], without changing the position of the people nor the
68 placement of the electrodes. Method agreement, calculated as the mean phase angle difference
69 (2SD) obtained from the Bio-Z[®] minus the RJL-101[®] or the Xitron[®], was -1.49° (0.45) and -
70 1.50 (0.24), respectively. We also calculated fat-free mass with the Geneva formula (9),
71 which was validated against DXA specifically in older persons (10). Fat mass was obtained
72 by subtracting fat-free mass from body weight. Fat-free mass index and fat mass index were
73 calculated as follows: fat-free mass or fat mass (kg)/body height (m)².

74 Date of death was considered until December 2012, and retrieved from the hospital
75 computer database, the death registry of the state of Geneva and the Swiss National Cohort
76 (11). We reported co-morbidities at the time of the BIA measurement in the form of the
77 Cumulative Illness Rating Scale (CIRS) (12). It rates 14 systems and organs from 0 (healthy)

78 to 4 (severe disease needing immediate intervention or hospitalization), and takes into account
79 lifestyle modes as smoking and alcohol consumption. Its final score ranges from 0 (healthy)
80 to 56 points.

81

82 Statistics

83 Results are shown as median (interquartile range) for continuous variables as they were not
84 normally distributed according to Shapiro-Wilk tests. Comparisons between devices were
85 performed with Kruskal-Wallis test.

86 Age, body mass index and CIRS were categorized like in our former study, because their
87 distribution, tested by Shapiro-Wilks test, was not normal: age as 65-74 yrs, 75-84 yrs and
88 ≥ 85 yrs, BMI as < 18.5 , 18.5-24.9, 25-29.9 and ≥ 30 kg/m² (13), and CIRS as quartiles of the
89 population measured by the considered device. The association between mortality and device-
90 and gender-specific phase angle quartiles were evaluated by univariate Cox regressions. We
91 performed multivariate Cox regressions with adjustments for age (model 1), BMI (model 2)
92 or CIRS categories (model 3) because we did not observe enough events to follow the rule of
93 Harrel (14). This rule supposes a maximum of 1 variable for 10 events.

94

95 **Results**

96 The characteristics of the study subjects measured by the different BIA devices are shown
97 in **table 1**. They were significantly different regarding age, body mass index, co-morbidities
98 and phase angle.

99 The small number of deaths in women (n=16) and men (n=39) who underwent a BIA
100 measurement by Xitron 4000B precluded the use of sex-specific phase angle quartiles in the
101 Cox regressions. We thus focused on the three other devices (n=1683). In sex-specific
102 univariate Cox regressions, the association between phase angle quartiles measured with the
103 Bio-Z[®] and RJL-101[®] devices and mortality could be highlighted, although the cut-off

104 quartiles differed between the BIA devices (**table 2**). No association between phase angle
105 and mortality was observed when using the Eugedia[®] device. Sex-specific multivariate Cox
106 regressions could be performed with the Bio-Z[®] and the RJL-101[®] device (**table 3**). They
107 confirmed the findings of univariate Cox regressions even when adjusting for age, BMI or
108 CIRS categories, i.e. the higher the phase angle quartile, the lower the death risk.

109

110 **Discussion**

111 This study shows that the mean phase angle values differed significantly between the
112 subjects measured with the Bio-Z[®], RJL-101[®], Eugedia[®] and Xitron[®] devices. A low phase
113 angle quartile was associated with a high death risk in people aged > 65 years, when using a
114 Bio-Z[®] or a RJL-101[®] device. When adjusting for age, body mass index or disease, a low
115 phase angle remained a risk factor of mortality.

116 The characteristics of the study population (age, BMI, diseases), or the technology itself
117 may explain the differences in phase angle values between the devices. Reference values for
118 phase angle are 7.7 and 10.5 % lower in the Swiss women and men (using several BIA brands
119 cross-calibrated for resistance) (15), and 12.5 and 16% lower in the German women and men
120 (using Data Input devices) (8) compared to the American population (using an RJL device)
121 (16). Bosy-Westphal et al. reported that a discrepancy of 0.3° for phase angle may be related
122 to differences between the Xitron[®] and Data Input devices, and that, although age and BMI
123 influence phase angle values, they do not explain the differences between populations (8).
124 This suggests that differences of phase angle values between our study groups may be related
125 to different anthropometric characteristics, BIA devices or other unidentified factors. Thus,
126 when evaluating the potential of a phase angle value on outcome at a population level, and in
127 the absence of a gold standard for phase angle measurement, it is essential to use a single
128 brand of BIA to avoid at least the confounding impact of different BIA devices.

129 Whether using an RJL-101[®] or a Bio-Z[®] device, a phase angle in the low quartile is
130 associated with a high risk of mortality. This result confirms our previous findings using a
131 Nutriguard[®] device but also other studies performed in older persons. A phase angle $< 3.5^\circ$,
132 measured by a Nutriguard[®] device at admission to a German hospital, increased the in-
133 hospital mortality by four times (17). Similarly, a phase angle in the lowest quintile (women:
134 $2.7\text{-}5.4^\circ$, men: $3.1\text{-}5.6^\circ$), measured by a Valhalla[®] device (Valhalla Scientific, San Diego, CA,
135 USA), led to a two-fold increase of mortality risk at 12 years (18). The adjustment for BMI,
136 age or CIRS did not change this association in our study. As a consequence, phase angle is
137 associated with mortality independently of these other mortality risk factors.

138 This study could demonstrate the link of phase angle and mortality with the RJL-101[®] and
139 the Bio-Z devices[®], but has several limitations. It is not a population-based study and our
140 subjects are likely more ill than the general population. However, the link between phase
141 angle and mortality was confirmed when adjusting for co-morbidities and their severity. We
142 did not use the different BIA devices in the same study population. This precludes the
143 comparison of phase angle values. Finally, the number of events (i.e. deaths) was not high
144 enough to make simultaneous adjustments for age, BMI and co-morbidities in the statistical
145 analyses.

146 Future studies should evaluate differences in electrical parameters between commonly
147 used BIA devices in large populations, in order to differentiate the variations related to
148 devices vs. population characteristics. They should also better identify the factors which
149 influence phase angle, especially in interventional studies with a longitudinal follow-up.

150

151 **Conclusion**

152 Phase angle quartiles are associated with mortality in people aged ≥ 65 years and older
153 when using other BIA devices than the Nutriguard[®], as the RJL-101[®] or the Bio-Z[®], although
154 the cut-offs of the phase angle quartiles differ.

155 **Acknowledgement**

156 We thank Gilles Cohen for exporting the medical data from the informatics hospital
157 database, Sylvain Ho and Anne-Marie Makhlouf for having reported the Cumulative Illness
158 Rating Scale, Kurt Schmidlin for performing the linkage to the Swiss National Cohort and
159 Claude Pichard and Véronique L. Karsegard for their constructive inputs during data analysis.

160

161 **Statement of authorship**

162 LG and CG designed the research; LG, FRH and CG analyzed data and performed statistical
163 analysis; LG and CG wrote the paper; LG has the primary responsibility for final content.

164

165 **Conflict of interest statement**

166 None of the authors have any conflict of interest.

167

168 **Funding sources**

169 This work was partly supported by the Research Fund of the Department of Internal Medicine
170 of the University Hospital and the Faculty of Medicine of Geneva. This fund receives an
171 unrestricted grant from AstraZeneca Switzerland. The Swiss National Cohort is funded by the
172 Swiss National Science Foundation (grant number 33CSC0_134273).

173 The funding source had no role in the design, analysis and interpretation of the data, nor in the
174 preparation of the manuscript and decision to submit the manuscript for publication.

175 **References**

- 176 1. Norman K, Stobaus N, Zocher D, Bosy-Westphal A, Szramek A, Scheufele R, et al.
177 Cutoff percentiles of bioelectrical phase angle predict functionality, quality of life, and
178 mortality in patients with cancer. *Am J Clin Nutr* 2010; 92: 612-9.
- 179 2. Thibault R, Makhoulouf AM, Mulliez A, Rotovnic Kozjek N, Gonzalez C, Kekstas G, et
180 al. Bioimpedance phase angle measured at admission predicts 28-day mortality in intensive
181 care unit patients: the international prospective observational study Phase Angle Project.
182 *Intensive Care Med* 2016; 42: 1445-53.
- 183 3. Colin-Ramirez E, Castillo-Martinez L, Orea-Tejeda A, Vazquez-Duran M, Rodriguez
184 AE, Keirns-Davis C. Bioelectrical impedance phase angle as a prognostic marker in chronic
185 heart failure. *Nutrition* 2012; 28: 901-5.
- 186 4. Gonzalez MC, Barbosa-Silva TG, Bielemann RM, Gallagher D, Heymsfield SB.
187 Phase angle and its determinants in healthy subjects: influence of body composition. *Am J*
188 *Clin Nutr* 2016; 103: 712-6.
- 189 5. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J, et al.
190 Bioelectrical impedance analysis-part II: utilization in clinical practice. *Clin Nutr* 2004; 23:
191 1430-53.
- 192 6. Graf C, Karsegard VL, Spoerri A, Makhoulouf A-M, Ho S, Herrmann FR, et al. Body
193 composition and all-cause mortality in subjects older than 65 y. *Am J Clin Nutr* 2015; 101:
194 760-7.
- 195 7. Genton L, Norman K, Spoerri A, Pichard C, Karsegard VL, Herrmann FR, et al.
196 Bioimpedance-derived phase angle and mortality among older people. *Rejuvenation Res*
197 2016. <http://dx.doi.org/10.1089/rej.2016.1879>
- 198 8. Bosy-Westphal A, Danielzik S, Dorhofer RP, Later W, Wiese S, Muller MJ. Phase
199 angle from bioelectrical impedance analysis: population reference values by age, sex, and
200 body mass index. *J Parenter Enteral Nutr* 2006; 30: 309-16.

- 201 9. Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation
202 for bioelectrical impedance analysis in adults aged 20--94 years. *Nutrition* 2001; 17: 248-53.
- 203 10. Genton L, Karsegard VL, Kyle UG, Hans DB, Michel JP, Pichard C. Comparison of
204 four bioelectrical impedance analysis formulas in healthy elderly subjects. *Gerontology* 2001;
205 47: 315-23.
- 206 11. Spoerri A, Zwahlen M, Egger M, Bopp M. The Swiss National Cohort: a unique
207 database for national and international researchers. *Int J Publ Health*. 2010;55(4):239-42.
- 208 12. Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, et al. A manual of
209 guidelines to score the modified cumulative illness rating scale and its validation in acute
210 hospitalized elderly patients. *J Am Geriatr Soc* 2008; 56: 1926-31.
- 211 13. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO
212 Consultation. WHO Tehnical Report Series 894. Geneva: World Health Organization, 2000.
- 213 14. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in
214 developing models, evaluating assumptions and adequacy, and measuring and reducing
215 errors. *Stat Med* 1996; 15: 361-87.
- 216 15. Kyle UG, Genton L, Slosman DO, Pichard C. Fat-free and fat mass percentiles in
217 5225 healthy subjects aged 15 to 98 years. *Nutrition* 2001; 17: 534-41.
- 218 16. Barbosa-Silva MC, Barros AJ, Wang J, Heymsfield SB, Pierson RN, Jr. Bioelectrical
219 impedance analysis: population reference values for phase angle by age and sex. *Am J Clin*
220 *Nutr* 2005; 82: 49-52.
- 221 17. Wirth R, Volkert D, Rosler A, Sieber CC, Bauer JM. Bioelectric impedance phase
222 angle is associated with hospital mortality of geriatric patients. *Arch Gerontol Geriatr*. 2010;
223 51: 290-4.
- 224 18. Wilhelm-Leen ER, Hall YN, Horwitz RI, Chertow GM. Phase angle, frailty and
225 mortality in older adults. *J Gen Int Med* 2014; 29: 147-54.
- 226

227 **Table 1:** Baseline characteristics at the last BIA measurements (n=1683)

	Bio-Z®				RJL-101®				Eugédia®				p*
	N	%	median	IQR	N	%	median	IQR	N	%	median	IQR	
Women													
Age (yrs)	424	100	77.0	11.0	266	100	80.0.2	12.0	185	100	75.0	10.0	<0.001
Age at death (yrs)	301	71	83.4	12.8	150	56	87.0	9.0	89	48	87.6	10.4	<0.001
Length of follow-up (yrs)#	424	100	5.8	9.2	266	100	15.3	15.1	185	100	16.7	6.6	<0.001
Phase angle (degrees)	424	100	3.4	1.4	266	100	4.2	1.4	185	100	4.1	1.0	<0.001
Resistance (Ω)	424	100	577.2	146.6	266	100	602.0	143.0	185	100	558.9	88.0	<0.001
Reactance (Ω)	424	100	34.8	17.0	266	100	45.0	19.0	185	100	40.0	11.0	<0.001
Body mass index (kg/m ²)	424	100	24.2	7.5	266	100	23.7	5.6	185	100	26.6	6.4	<0.001
Fat mass index (kg/m ²)	424	100	9.3	5.1	266	100	8.6	3.6	185	100	10.5	4.0	<0.001
Fat-free mass index (kg/m ²)	424	100	14.8	3.5	266	100	14.8	2.4	185	100	16.0	3.0	<0.001
Cumulative Illness Rating Scale	393	93	10.0	8.0	154	58	5.0	5.0	114	62	3.0	5.0	<0.001
Men													
Age (yrs)	501	100	75.0	10.0	190	100	74.0	12.0	117	100	73.0	10.0	<0.001
Age at death (yrs)	397	79	78.9	10.8	106	56	82.5	12.7	53	45	83.5	11.2	<0.001
Length of follow-up (yrs)	501	100	3.4	8.8	190	100	14.7	17.4	117	100	17.1	9.4	<0.001
Phase angle (degrees)	501	100	3.7	1.7	190	100	4.9	1.8	117	100	4.6	1.7	<0.001
Resistance (Ω)	501	100	486.5	116.6	190	100	506.5	92.0	117	100	489.1	89.0	<0.001
Reactance (Ω)	501	100	30.8	13.7	190	100	42.0	17.0	117	100	39.2	10.6	<0.001
Body mass index (kg/m ²)	501	100	24.5	5.6	190	100	24.5	4.2	117	100	26.2	4.8	<0.001
Fat mass index (kg/m ²)	501	100	6.7	3.6	190	100	6.7	3.2	117	100	7.6	3.0	<0.001
Fat-free mass index (kg/m ²)	501	100	18.0	3.6	190	100	18.0	2.3	117	100	18.4	2.8	<0.001
Cumulative Illness Rating Scale	393	93	10.0	8.0	154	58	5.0	5.0	114	62	3.0	5.0	<0.001

228 IQR: interquartile range; # Time between the BIA measurements and death or censoring (31.12. 2011); * Comparisons between devices: Wilcoxon rank-sum U test

230 **Table 2:** Univariate Cox regression models evaluating the association of phase angles quartiles, measured by different BIA devices, and mortality.

	Women				Men			
	n	Cut-off	HR	95% CI	n	Cut-off	HR	95% CI
Bio-Z®	424				501			
Quartile 1	106	0.10-2.69	1.00	-	126	0.10-2.79	1.00	-
Quartile 2	106	2.70-3.39	0.63	0.47, 0.85	125	2.80-3.69	0.67	0.52, 0.88
Quartile 3	106	3.40-4.10	0.41	0.30, 0.57	125	3.70-4.50	0.54	0.42, 0.71
Quartile 4	106	4.10-7.40	0.36	0.26, 0.50	125	4.50-7.40	0.38	0.29, 0.51
RJL-101®	266				190			
Quartile 1	67	1.58-3.51	1.00	-	48	0.91-3.85	1.00	-
Quartile 2	66	3.52-4.18	0.78	0.52, 1.17	47	3.88-4.90	0.76	0.48, 1.20
Quartile 3	67	4.19-4.93	0.40	0.26, 0.62	48	4.91-5.60	0.36	0.21, 0.61
Quartile 4	66	4.94-11.64	0.23	0.14, 0.39	47	5.61-9.51	0.19	0.10, 0.36
Eugédia®	185				117			
Quartile 1	47	0.1-3.5	1.00	-	31	0.9-3.6	1.00	
Quartile 2	46	3.6-4.1	1.39	0.79, 2.42	28	3.7-4.5	0.91	0.42, 1.96
Quartile 3	46	4.1-4.6	0.69	0.37, 1.28	29	4.6-5.3	1.03	0.50, 2.14
Quartile 4	46	4.7-6.4	0.72	0.39, 1.32	29	5.4-7.7	0.76	0.35, 1.65

231

232

233 **Table 3:** Multivariate Cox regression models evaluating the association of phase angles quartiles, measured by different BIA devices, and
 234 mortality.

	Bio-Z®						RJL-101®					
	Women			Men			Women			Men		
	n	HR	95% CI	n	HR	95% CI	n	HR	95% CI	n	HR	95% CI
Model 1	424			501			266			190		
Quartile 1		1.00	-		1.00	-		1.00	-		1.00	-
Quartile 2		0.63	0.47, 0.85		0.67	0.52, 0.88		0.73	0.49, 1.11		0.68	0.42, 1.09
Quartile 3		0.41	0.30, 0.56		0.56	0.43, 0.73		0.36	0.23, 0.57		0.34	0.20, 0.59
Quartile 4		0.41	0.29, 0.57		0.41	0.30, 0.54		0.19	0.10, 0.34		0.16	0.08, 0.31
Model 2	424			501			266			190		
Quartile 1		1.00	-		1.00	-		1.00	-		1.00	-
Quartile 2		0.62	0.46, 0.85		0.70	0.53, 0.91		0.78	0.52, 1.18		0.75	0.47, 1.20
Quartile 3		0.40	0.29, 0.56		0.58	0.44, 0.76		0.41	0.26, 0.63		0.35	0.20, 0.62
Quartile 4		0.35	0.25, 0.49		0.42	0.31, 0.57		0.23	0.14, 0.39		0.19	0.10, 0.35
Model 3	393			481			154			107		
Quartile 1		1.00	-		1.00	-		1.00	-		1.00	-
Quartile 2		0.77	0.57, 1.04		0.71	0.54, 0.93		0.73	0.45, 1.19		0.67	0.40, 1.12
Quartile 3		0.55	0.39, 0.76		0.66	0.50, 0.87		0.42	0.25, 0.71		0.48	0.25, 0.91
Quartile 4		0.53	0.38, 0.75		0.51	0.38, 0.68		0.42	0.22, 0.77		0.36	0.16, 0.78

235 Model 1: adjusted for age category; model 2: adjusted for BMI category; model 3: adjusted for CIRS quartiles

236